AGIOS PHARMACEUTICALS

Agios to Participate in December Investor Conference

30 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

10 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition

03 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2022 Financial Results

03 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty

27 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022

20 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

26 Sep 2022 18:13:07 By Nasdaq GlobeNewswire

Agios Appoints Cecilia Jones as Chief Financial Officer

19 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

16 Sep 2022 05:41:44 By Nasdaq GlobeNewswire

Agios to Participate in September Investor Conferences

24 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

18 Aug 2022 17:35:00 By Nasdaq GlobeNewswire

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

15 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

11 Aug 2022 17:35:00 By Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

08 Aug 2022 17:36:08 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

04 Aug 2022 06:00:02 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

14 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Agios Appoints Brian Goff as Chief Executive Officer

12 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

10 Jun 2022 09:30:00 By Nasdaq GlobeNewswire

Agios Announces Evolution of Research Organization

16 May 2022 15:15:00 By Nasdaq GlobeNewswire

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

12 May 2022 09:00:00 By Nasdaq GlobeNewswire